Tony Jolliffe/BBC News
Материалы по теме:
，推荐阅读safew官方版本下载获取更多信息
有趣的是，Infigratinib最初于2021年获批用于胆管癌，后因适应症开发策略调整而主动撤回。如今，其有望在ACH赛道迎来“第二春”。基于其疗效和口服便利性，BridgeBio在今年的JPM大会上预测，该药Infigratinib将占据ACH治疗市场50%以上的份额。。关于这个话题，heLLoword翻译官方下载提供了深入分析
"I think of my donor and her family every day and pray they find some peace in knowing their daughter gave me the biggest gift: the gift of life," Bell said.